| Title | Cognitive Impairment and Cerebral Hypoperfusion in a CADASIL Patient Improved During Administration of Lomerizine. | | Author(s) | Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, Isayama R, Hosomi A, Nagakane Y, Tokuda T, Sugimoto E, Ushijima Y, Nakagawa M | | Source | Clin Neuropharmacol 2009 Mar-Apr; 32(2):113-6. | | Abstract | A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19512965 |
|
